Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease.

Argüelles Arias, FedericoHinojosa Del Val, JoaquínVera Mendoza, Isabel2023-01-252023-01-2520181130-0108http://hdl.handle.net/10668/12230In 2013, the European Medicines Agency (EMA) approved the biosimilar infliximab (CT-P13) for the full range of indications of the originator product, based on data from two trials conducted in rheumatoid arthritis and ankylosing spondylitis. The same year, our Society published a position statement that was later reviewed.enAnti-Inflammatory AgentsBiosimilar PharmaceuticalsHumansInflammatory Bowel DiseasesInfliximabPractice Guidelines as TopicUpdate of the SEPD position statement on the use of biosimilars for inflammatory bowel disease.research article29527903open access10.17235/reed.2018.5456/2018https://doi.org/10.17235/reed.2018.5456/2018